Kamada N, Shinomiya T, Tamaki T, Ishiguro K
Transplantation. 1986 Dec;42(6):581-7. doi: 10.1097/00007890-198612000-00002.
Immunological enhancement of allogeneic heart graft survival by serum from rats tolerized by liver grafting has been studied. Serum taken from long-term-surviving PVG rats carrying orthotopic DA liver transplants (OLT serum) was able to increase the survival time of PVG.RT1a heterotopic heart grafts in PVG recipients. Administration of 1 ml of OLT serum at the time of heart grafting led to permanent survival of the grafts in all animals. The recipients became systemically tolerant of RT1a and several weeks later were able to accept permanently skin grafts from the same donor strain, while rejecting third-party grafts. Enhancement appeared to be mediated initially by IgG antibodies in the OLT serum against class II donor RT1a antigens; significant enhancement was produced by as little as 100 micrograms of antibody. Recipient alloantibody responses following enhancement were studied and showed selective suppression of the anti-class-I (RT1Aa) antibody levels, while the anti-class-II antibody response was apparently unaffected. The implications of these results for mechanisms of unresponsiveness following enhancement and liver transplantation are discussed.
研究了通过肝移植耐受大鼠的血清对同种异体心脏移植存活的免疫增强作用。从长期存活的携带原位DA肝移植的PVG大鼠（OLT血清）中获取的血清能够延长PVG受体中PVG.RT1a异位心脏移植的存活时间。在心脏移植时给予1ml OLT血清可使所有动物的移植心脏永久存活。受体对RT1a产生全身性耐受，几周后能够永久接受来自同一供体品系的皮肤移植，同时排斥第三方移植。增强作用最初似乎是由OLT血清中针对II类供体RT1a抗原的IgG抗体介导的；低至100微克的抗体就能产生显著增强作用。研究了增强作用后受体的同种异体抗体反应，结果显示抗I类（RT1Aa）抗体水平受到选择性抑制，而抗II类抗体反应显然未受影响。讨论了这些结果对增强作用和肝移植后无反应机制的意义。
